| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K63431240 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | CP466722 | GDSC1000 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | Parthenolide | GDSC1000 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | -0.0061 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |